Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 213
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Dairy Sci ; 96(3): 1745-54, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23332842

RESUMO

Products of different origin, time of collection, and activities fall under the general term of colostrum and, therefore, great variability in composition as well as in the concentration of its components has been reported in the literature. In the present study, we describe the standardization of a bovine colostrum derivative and the characterization of its bioactive components. Evaluation of the most representative agents (lactoferrin, transferrin, IL-2, IFN-γ, tumor necrosis factor, IgG, and IgA) showed that a marked decrease in active components occurs after the first few hours. Bovine colostrum was, therefore, collected up to the fifth hour after delivery from Holstein cows, in the presence of preservatives, and immediately frozen. A protocol of centrifugation, filtration, and lyophilization was then applied to pools of colostrum from at least 30 cows to obtain a stable, sterile, standardized product. Preservatives were removed by dialysis. Evaluation of the active biological components of colostrum showed that the final product of colostrums contained significant and reproducible amounts of bioactive factors, including cytokines, immunomodulating factors, growth factors, and immunoglobulins. The final product appeared, therefore, as a sterile, pyrogen-free, standardized derivative of bovine colostrum with a high concentration of bioactive components.


Assuntos
Colostro/química , Animais , Carga Bacteriana/veterinária , Bovinos , Colostro/microbiologia , Ensaio de Imunoadsorção Enzimática/veterinária , Feminino , Imunoglobulina A/análise , Imunoglobulina G/análise , Interferon gama/análise , Interleucina-2/análise , Lactoferrina/análise , Fatores de Tempo , Transferrina/análise , Fator de Necrose Tumoral alfa/análise
2.
Int J Immunopathol Pharmacol ; 23(3): 847-55, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20943056

RESUMO

Chronic alcohol use has profound modulatory effects on the immune system. Both the innate and the acquired immunity are compromised. The use of pharmacotherapy is increasingly applied to enhance the percentage of success in maintaining alcoholic patients in remission. Disulfiram, naltrexone and gamma hydroxybutiric acid are the drugs used for this purpose in Italian Addiction Services. In this study we analyze the effect of pharmacotherapy of alcohol dependence on immune responses in alcoholics. Six groups were studied. Group A included 10 patients who were still using alcohol. Group B consisted of 10 patients abstinent from alcohol in treatment only with group therapy. Groups C, D and E were composed of 10 patients each, treated for at least 6 months with oral doses of gamma hydroxybutiric acid, naltrexone or disulfiram respectively. Ten age- and sex-matched healthy volunteers who never misused alcohol were included as a control group. Lymphoproliferation and peripheral mononuclear cell production of the Th1 cytokines IL-2 and IFN-gamma, the Th2 cytokine IL-4, and of the pro-inflammatory cytokines IL-1 and TNF-alpha were evaluated in all the patients and controls. The level of activity of the hypothalamus pituitary adrenal axis was assessed. Both ACTH and cortisol levels in plasma were elevated in alcoholic patients with no treatment. In this group a significant alteration of cytokine production was observed. TNF and IFN-gamma were lower than controls, while the Th2 cytokine IL-4 was increased. These altered levels state for a Th1/Th2 unbalance characterized by decreased Th1 response in the presence of Th2 predominance. In patients undergoing pharmacological treatment, none of the immune parameters were different from those observed in healthy controls, independently of the type of drug administered. These data indicate that pharmacotherapy more than group therapy treatment is able to ameliorate the immune system functioning in alcoholic patients.


Assuntos
Dissuasores de Álcool/uso terapêutico , Alcoolismo/tratamento farmacológico , Alcoolismo/imunologia , Hormônio Adrenocorticotrópico/sangue , Adulto , Alcoolismo/psicologia , Proliferação de Células/efeitos dos fármacos , Citocinas/biossíntese , Manual Diagnóstico e Estatístico de Transtornos Mentais , Feminino , Humanos , Hidrocortisona/sangue , Sistema Hipotálamo-Hipofisário/metabolismo , Imunidade Celular/efeitos dos fármacos , Interleucina-1/biossíntese , Linfócitos/efeitos dos fármacos , Linfócitos/imunologia , Masculino , Pessoa de Meia-Idade , Fatores Socioeconômicos , Células Th1/efeitos dos fármacos , Células Th1/metabolismo , Células Th2/efeitos dos fármacos , Células Th2/metabolismo , Fator de Necrose Tumoral alfa/biossíntese
3.
Science ; 203(4385): 1129-31, 1979 Mar 16.
Artigo em Inglês | MEDLINE | ID: mdl-424743

RESUMO

Subcutaneous injections of naloxone, an opiate antagonist, lead to an increase in serum luteinizing hormone concentrations in female but not in male rats before they reach puberty. In addition, estradiol benzoate specifically blocks the luteinizing hormone response to naloxone in prepubertal female rats, suggesting that the opioid peptides have a physiological role in the endocrine events leading to sexual maturation.


Assuntos
Endorfinas/fisiologia , Hormônio Luteinizante/metabolismo , Maturidade Sexual/efeitos dos fármacos , Animais , Endorfinas/antagonistas & inibidores , Estradiol/farmacologia , Feminino , Hormônio Luteinizante/sangue , Masculino , Naloxona/antagonistas & inibidores , Naloxona/farmacologia , Ratos , Taxa Secretória/efeitos dos fármacos
4.
Brain Res ; 1199: 74-81, 2008 Mar 14.
Artigo em Inglês | MEDLINE | ID: mdl-18302958

RESUMO

Recent evidence suggest that ATP plays a role as an endogenous pain mediator generating and/or modulating pain signaling from the periphery to the spinal cord. In this study we evaluated the effects of intraperitoneal administration of P2 receptor antagonist, pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), evaluating pain related behaviours and monitoring the expression of Fos, a marker of activated neurons, in an experimental mouse model of neuropathic pain (sciatic nerve tying). The PPADS administration decreased both tactile allodynia and thermal hyperalgesia in a time and dose dependent manner. The dose of 25 mg/kg PPADS completely reversed nociceptive hypersensitivity. Moreover, non-noxious stimulation induced an increase of Fos positive neurons in the spinal cord of animals with tying of sciatic nerve. PPADS administration partially reversed this increase. These results suggest that PPADS reduces neuronal activation at spinal cord level and that P2 receptors are involved in the retrograde signalling progress exciting sensory spinal neurons.


Assuntos
Regulação para Baixo/efeitos dos fármacos , Proteínas Oncogênicas v-fos/metabolismo , Inibidores da Agregação Plaquetária/administração & dosagem , Fosfato de Piridoxal/análogos & derivados , Neuropatia Ciática/patologia , Medula Espinal/metabolismo , Análise de Variância , Animais , Comportamento Animal , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Hiperalgesia/tratamento farmacológico , Hiperalgesia/fisiopatologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Medição da Dor/métodos , Limiar da Dor/efeitos dos fármacos , Fosfato de Piridoxal/administração & dosagem , Neuropatia Ciática/tratamento farmacológico , Neuropatia Ciática/fisiopatologia , Medula Espinal/efeitos dos fármacos
5.
J Neuroimmunol ; 159(1-2): 97-105, 2005 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15652407

RESUMO

Cannabidiol is the main nonpsychoactive component of marijuana. We examined the ability of in vivo and in vitro cannabidiol to interfere with the production of interleukin (IL)-12 and IL-10 by murine macrophages and to modulate macrophage chemotaxis. Cannabidiol added in vitro to peritoneal macrophages significantly increased IL-12 and decreased IL-10 production. The CB1 and CB2 receptor antagonists prevented this modulation. Macrophages from animals treated with cannabidiol at the dose of 30 mg kg(-1) either orally or i.p. produced higher levels of IL-12 and lower levels of IL-10 in comparison to controls, and the CB receptor antagonists did not prevent these effects. Cannabidiol dose-dependently decreased fMLP-induced chemotaxis of macrophages, and the CB2 receptor antagonist prevented this decrease.


Assuntos
Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/farmacologia , Canabidiol/administração & dosagem , Canabidiol/farmacologia , Quimiotaxia/efeitos dos fármacos , Interleucina-10/biossíntese , Interleucina-12/biossíntese , Macrófagos Peritoneais/efeitos dos fármacos , Adjuvantes Imunológicos/metabolismo , Administração Oral , Animais , Canfanos/farmacologia , Canabidiol/metabolismo , Inibição de Migração Celular , Células Cultivadas , Quimiotaxia/imunologia , Citocinas/biossíntese , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/imunologia , Interleucina-10/antagonistas & inibidores , Ativação de Macrófagos/efeitos dos fármacos , Ativação de Macrófagos/imunologia , Macrófagos Peritoneais/imunologia , Macrófagos Peritoneais/metabolismo , Masculino , Camundongos , Piperidinas/farmacologia , Pirazóis/farmacologia , Receptor CB1 de Canabinoide/antagonistas & inibidores , Receptor CB1 de Canabinoide/fisiologia , Receptor CB2 de Canabinoide/antagonistas & inibidores , Receptor CB2 de Canabinoide/fisiologia , Rimonabanto , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/imunologia
6.
Endocrinology ; 135(4): 1346-52, 1994 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-7925095

RESUMO

The opioid peptide beta-endorphin (BE) is synthesized and secreted by the cells of the immune system and has been shown to participate in the modulation of immune responses, e.g. during stress. Interleukin-1 (IL-1) is a potent activator of the corticotropin-releasing hormone (CRH) system in the hypothalamus, and it has been shown to be involved in many stress responses, including immunosuppression. We studied the effect of centrally injected IL-1 alpha on immunocyte BE concentrations in the rat. IL-1 alpha (1 ng/rat, intracerebroventricularly) significantly (P < 0.01) increased the concentrations of the peptide in splenocytes, lymph node cells, and peripheral blood mononuclear cells 2 and 24 h after treatment. Intracerebroventricular, but not iv, administration of 2 micrograms IL-1 receptor antagonist blocked the IL-1 alpha-induced increase. These effects were also prevented by the intracerebroventricular administration of the CRH receptor antagonist alpha-helical CRH-(9-41). Treatment with 6-hydroxydopamine and 5,7-dihydroxytryptamine, which deplete the catecholaminergic or the serotoninergic systems, respectively, blocked the increase in BE induced by the cytokine. In contrast, hypophysectomy and treatment with indomethacin did not modify the effect of IL. The increase in immunocyte BE, therefore, seems to depend on the activation of CRH, catecholamines, and serotonin, but to be independent of activation of the hypothalamus-pituitary-adrenal-axis and prostaglandins. The immunocyte BE increase could be involved in the immunosuppression induced by central IL-1 alpha.


Assuntos
Catecolaminas/fisiologia , Hormônio Liberador da Corticotropina/fisiologia , Interleucina-1/farmacologia , Linfonodos/citologia , Linfonodos/metabolismo , Serotonina/fisiologia , Baço/citologia , Baço/metabolismo , beta-Endorfina/análise , beta-Endorfina/metabolismo , Adrenalectomia , Animais , Catecolaminas/metabolismo , Hormônio Liberador da Corticotropina/antagonistas & inibidores , Hipofisectomia , Indometacina/farmacologia , Injeções Intraventriculares , Interleucina-1/administração & dosagem , Linfonodos/química , Masculino , Radioimunoensaio , Ratos , Ratos Sprague-Dawley , Serotonina/metabolismo , Baço/química
7.
Endocrinology ; 117(3): 1096-9, 1985 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-2990867

RESUMO

We evaluated plasma PRL and LH concentrations in the rat after the administration of drugs that exert a specificity directed mainly, although not absolutely, toward the mu-, delta-, or kappa-opiate receptors, in order to investigate the role of different receptors and thus the respective endogenous ligands in the modulation of the release of these anterior pituitary hormones. LH concentrations were evaluated in prepuberal female rats, in adult male rats, and in ovariectomized, estradiol benzoate-treated rats. PRL concentrations were evaluated in suckling rats, in ovariectomized, estradiol benzoate-treated rats, and in ether-stressed rats. The delta-antagonist ICI 154129 never affected PRL or LH concentrations, whereas both the mu- and kappa-antagonists, naloxone and MR 1452, respectively, seemed to be effective. However, when graded doses of the two classes of antagonists were tested, the mu-antagonist appeared to be effective on both hormones at doses that were one tenth of those of the kappa-antagonist. In conclusion, the mu-receptor seems to be the most profoundly involved in the regulation of PRL and LH secretion.


Assuntos
Hormônio Luteinizante/sangue , Prolactina/sangue , Receptores Opioides/fisiologia , Animais , Animais Lactentes , Benzomorfanos/farmacologia , Castração , Encefalina Leucina/análogos & derivados , Encefalina Leucina/farmacologia , Estradiol/farmacologia , Feminino , Masculino , Naloxona/farmacologia , Ratos , Ratos Endogâmicos , Receptores Opioides mu , Maturidade Sexual
8.
Endocrinology ; 104(1): 237-42, 1979 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-109274

RESUMO

A study was made of the effect of TRH, administered in vivo by iv infusion or added in vitro to the incubation fluid, on tissue fragments prepared from rat normotopic and ectopic pituitaries. The latter were 30-day-old pituitary grafts transplanted under the kidney capsule in hypophysectomized animals. No detectable effect of TRH was found with normotopic glands. In contrast, the neurohormone produced a large increase in GH and PRL biosynthesis in the grafts, as revealed by the rise in hormone content as well as increased incorporation of L-[3H]leucine into the two hormones. These effects of TRH 1) are dose related; 2) appear after a latent period of at least 15 min; and 3) persist, although attenuated, for some time after removing the neurohormone. In vitro release of GH and PRL by tissue fragments prelabeled with L-[3H]leucine was studied by following the appearance of the radioactive hormones in the incubation fluid. Exposure to TRH produced a prompt, 2-fold or greater increase in hormone release from grafts but not from normotopic gland fragments. The possible mechanisms whereby pituitary somatotrophs and mammotrophs removed from the influence of the central nervous system increase their responsiveness to TRH stimulation are considered.


Assuntos
Hormônio do Crescimento/metabolismo , Hipófise/transplante , Prolactina/metabolismo , Hormônio Liberador de Tireotropina/farmacologia , Animais , Feminino , Cinética , Hipófise/efeitos dos fármacos , Hipófise/metabolismo , Biossíntese de Proteínas/efeitos dos fármacos , Ratos , Transplante Homólogo
9.
Endocrinology ; 104(1): 226-36, 1979 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-446350

RESUMO

Homologous anterior pituitaries grafted under the kidney capsule in hypophysectomized rats were studied 30 days after transplantation. Some cells maintained the ultrastructural features peculiar to the various cell types of normotopic glands, while the others were characterized by few, small, dense granules, spherical or polymorphic, located peripherally in the cytoplasm. This picture might be due to a functional adaptation which occurs in pituitary cells still producing different hormones, once removed from central nervous system control. The major change in polypeptide hormone composition of graft homogenates relative to normotopic pituitaries is the fall in GH and PRL concentration. The in vitro incorporation of L-[3H]leucine into the two hormones and the release of radioactive GH and PRL from L-[3H]leucine-prelabeled tissue fragments are also greatly decreased. The decrease in concentration, in vitro biosynthesis, and release of GH per mg tissue protein are approximately 87, 91, and 93%, respectively. These results might be due primarily to a decrease in the number of somatotrophs and/or in their secretory activity, with relatively minor changes in GH intracellular transport and turnover. In contrast, a clear-cut fall in in vitro turnover was detected for PRL, as shown by the fact that decreases in biosynthesis and release per mg tissue protein of this hormone (approximately -95% and -99%, respectively) by far exceed the decrease in the tissue concentration (-74%). These data indicate that in in vitro secretory activity of mammotrophs is greatly reduced in the grafts with respect to the normotopic glands. Thus, the high secretory activity previously reported in hypophysectomized rats bearing pituitary grafts should be attributed to the lack of the inhibitory control of the central nervous system rather than to an increase in secretory capacity under nonrestrained conditions.


Assuntos
Hormônio do Crescimento/metabolismo , Hipófise/transplante , Prolactina/metabolismo , Animais , Feminino , Hipofisectomia , Hipófise/citologia , Hipófise/metabolismo , Biossíntese de Proteínas , Ratos , Transplante Homólogo
10.
Endocrinology ; 108(6): 2400-2, 1981 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-7227313

RESUMO

This study was conducted in order to further understand whether the effect of opiates on growth hormone and prolactin release was exerted centrally or at least in part peripherally. Male rats were treated with morphine-HCl after pretreatment with saline with either the opiate antagonist naloxone-HCl or the quaternary derivative naloxone methyl bromide (Naloxone-Br), the latter of which does not cross the blood brain barrier. Morphine-HCl elicited a clear cut increase in prolactin and growth hormone release after pretreatment with naloxone-Br, but not after pretreatment with naloxone-HCl. Naloxone-Br, however, was able to inhibit the effect of morphine when administered directly in the brain ventricles. To further confirm these results, we administered the quaternary derivative morphine-methyl-iodide (morphine-I), which unlike morphine-HCl, does not cross the blood brain barrier. Morphine-I was ineffective in eliciting growth hormone and prolactin release when administered peripherally, but was effective when administered intraventricularly.


Assuntos
Hormônio do Crescimento/metabolismo , Morfina/farmacologia , Prolactina/metabolismo , Animais , Barreira Hematoencefálica , Relação Dose-Resposta a Droga , Masculino , Morfina/antagonistas & inibidores , Naloxona/farmacologia , Ratos
11.
Endocrinology ; 98(3): 807-14, 1976 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-816640

RESUMO

Hypophysectomized female rats which received renal grafts of anterior pituitary (AP) or weight-matched intact controls were sampled under urethane anesthesia. Plasma growth hormone (GH) in sequential samples from each rat was measured by radioimmunoassay to determine the effect of exogenous thyrotropin-releasing hormone (TRH) on GH release from ectopic or intact AP. In a first experiment, following a baseline sample, a pre-treatment sample was taken from each rat 30 min after urethane injection, after which TRH (0.3 or 0.6 mug) or isotonic saline was injected iv, and samples were taken at 10 and 30 min post-treatment. Baseline GH levels in hypophysectomized-transplanted rats were in the range of 4.0 to 8.0 ng/ml, and were not modified significantly by urethane. TRH caused a significantly greater increase in growth hormone at 10 min than did saline. Plasma GH tended to be higher at 30 min post-treatment only in the 0.6 mug TRH-treated group. In further experiments the above described protocol was followed except that four doses of TRH were used (0.15, 0.3, 0.6, and 1.2 mug) and post-TRH blood samples were taken at 5 and 10 min. TRH caused a clear-cut increase in plasma GH both at 5 and 10 min, although no dose-effect relationship was present. In intact controls, baseline GH levels were in the range 40.0 to 80.0 ng/ml and were drastically reduced by urethane. In these animals, only the 1.2 mug TRH dose induced a GH rise at 5 and 10 min. In similar experiments, iv administration of vasopressin (100, 200, or 400 mU) induced a rise in plasma GH when given to the hypohysectomized-transplanted rats, but was ineffective in intact controls; the administration of prostaglandin E2 (5.0 and 50.0 mug) increased plasma GH in both experimental conditions. The results indicate that TRH in the hypophysectomized-transplanted rat acts directly on the AP tissue to increase GH release and that the ectopic pituitary is more susceptible than the in situ pituitary to some GH-releasing stimuli.


Assuntos
Hormônio do Crescimento/metabolismo , Adeno-Hipófise/transplante , Hipófise/transplante , Hormônio Liberador de Tireotropina/farmacologia , Animais , Feminino , Rim/cirurgia , Adeno-Hipófise/efeitos dos fármacos , Adeno-Hipófise/metabolismo , Prostaglandinas E/farmacologia , Ratos , Fatores de Tempo , Transplante Homólogo , Uretana/farmacologia , Vasopressinas/farmacologia
12.
Endocrinology ; 100(6): 1663-71, 1977 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-404131

RESUMO

The growth hormone (GH)-releasing effect of thyrotropin-releasing hormone (TRH) was investigated in rats in which central nervous system (CNS)-anterior pituitary (AP) connections had been experimentally interrupted. Sprague-Dawley (SD) female and male rats, underwent bilateral electrolytic lesions in the median eminence (ME) or the ventromedial nuclei (VMN) or were sham-operated (sham-op). Fifteen days after surgery, 0.9% NAACl or TRH was injected iv into sham-op rats or those with lesions in the CNS, anesthetized with urethane, and blood was drawn at 5 and 10 min posttreatment. In the rats with ME lesions, TRH at all the doses used (0.1, 0.4 and 0.8 microng/100 g BW) induced a marked, although not dose-related GH rise, which was not present in sham-op rats after TRH, or after NaCl administration to either rats with ME lesions or sham-op rats. In SD male rats lesioned in the VMN, TRH at doses of 0.4 and 0.8 microng/100 g BW induced significant GH rises, while the lowest TRH dose (0.1 microng/100 g BW) was ineffective; again, TRH was ineffective at all doses used in sham-op rats. Concomitant evaluation of the prolactin (PRL)-releasing effect of TRH (0.1-0.8 microng/100 g BW), showed a striking elevation of plasma PRL in both female and male sham-op controls, but no PRL rise in the rats with ME lesions. The results reveal that in the rat with surgical separation of the anterior pituitary from the CNS, a direct GH-releasing effect of TRH can be obtained, whereas its PRL-releasing effect is no longer observed, and suggest that, by analogy, the GH-releasing effect of TRH present in some disease states of the human may be due to an impairment of CNS-AP connections.


Assuntos
Hormônio Liberador de Hormônio do Crescimento/fisiologia , Hipotálamo/fisiologia , Hormônio Liberador de Tireotropina/farmacologia , Animais , Clorpromazina/farmacologia , Feminino , Hormônio do Crescimento/sangue , Masculino , Eminência Mediana/fisiologia , Adeno-Hipófise/anatomia & histologia , Adeno-Hipófise/metabolismo , Prolactina/sangue , Ratos
13.
J Clin Endocrinol Metab ; 70(1): 141-8, 1990 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-1967176

RESUMO

Neuropeptides are common mediators of the nervous and the immune systems. We investigated whether two families of peptides, calcitonin (CT) and somatostatin, posses human monocyte chemotactic activity. CT-related peptides induce a significant chemotactic response, and the potency order is: salmon CT greater than human CT greater than CT much greater than carbo-CT; CT gene-related peptide is completely inactive. This rank potency order differs from that in other systems (e.g. bone and nervous system). The chemotactic response of monocytes obtained from patients chronically treated with either salmon CT or carbo-CT is impaired, thus suggesting a phenomenon of down-regulation of a common receptor on monocytes. While somatostatin-(1-14) is completely inactive on monocyte chemotaxis, the synthetic analog SMS 201995 is extremely potent. Also, in this case the prolonged treatment of patients with SMS 201995 leads to an impaired chemotactic response.


Assuntos
Calcitonina/farmacologia , Quimiotaxia de Leucócito/efeitos dos fármacos , Somatostatina/farmacologia , Animais , Regulação para Baixo/efeitos dos fármacos , Enguias , Humanos , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/imunologia , Matemática , Octreotida/farmacologia , Salmão
14.
J Clin Endocrinol Metab ; 41(1): 143-8, 1975 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-168228

RESUMO

Plasma ACTH levels after oral and iv metyrapone administration were studied in 7 and 5 healthy women respectively both under basal conditions and after a 4-day treatment with metergoline, a specific antiserotoninergic agent. In 3 additional women, the effects of methysergide, another antiserotoninergic drug, on the plasma ACTH rise induced by oral metyrapone, were evaluated. A significant lowering of the plasma ACTH levels attained after either oral or iv metyrapone was observed following metergoline administration: 149+/-64.3 vs 239+/-49.1 pg/ml (mean peak values), P less than 0.05 in the oral test and 331+/-19.7 vs 221+/-19.5 pg/ml, P less than 0.02 in the iv test. The fall of plasma cortisol caused by metyrapone was comparable before and after the antiserotoninergic treatment. An interference of metergoline in the ACTH radioimmunoassay was also excluded. After metergoline administration, a slight reduction in the baseline plasma ACTH values was noted: 79+/-7.7 vs 67+/-7.7 pg/ml (NS). A decrease, however not statistically significant, of the metyrapone-induced plasma ACTH elevation occured after methysergide administration: 421+/-150.7 vs 344+/-135.1 pg/ml. These results can be interpreted as indicating that antiserotoninergic treatment caused an inhibition of hypophysial ACTH release in response to metyrapone. Caution is recommended, however, before concluding, on the basis of these findings, that serotonin as such plays a physiological stimulating role on ACTH secretion.


Assuntos
Hormônio Adrenocorticotrópico/sangue , Ergolinas/farmacologia , Metergolina/farmacologia , Metisergida/farmacologia , Metirapona/farmacologia , Antagonistas da Serotonina , Administração Oral , Adulto , Feminino , Humanos , Hidrocortisona/sangue , Infusões Parenterais , Cinética , Metirapona/administração & dosagem , Metirapona/antagonistas & inibidores , Pessoa de Meia-Idade , Radioimunoensaio
15.
J Clin Endocrinol Metab ; 45(1): 134-40, 1977 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-406272

RESUMO

Thyrotropin-releasing hormone (TRH) was administered iv to 10 patients with severe liver disease and 10 control subjects. Injection of 400 microgram TRH as a bolus induced in 7 out of 10 patients a clear-cut GH rise (larger than or equal 10 ng/ml) occurring 15-120 min after the injection, and no effect on GH levels in controls. Mean baseline GH levels wre higher in patients than in controls. An exaggerated and sustained PRL rise was present after TRH in the subjects with liver disease, whose mean baseline plasma PRL levels were within normal range.


Assuntos
Hormônio do Crescimento/sangue , Hepatite/sangue , Cirrose Hepática/sangue , Prolactina/sangue , Hormônio Liberador de Tireotropina , Adulto , Fosfatase Alcalina/sangue , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Glicemia/metabolismo , Colinesterases/sangue , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Albumina Sérica/análise , Triptofano/sangue , Ureia/sangue
16.
J Clin Endocrinol Metab ; 44(5): 870-5, 1977 May.
Artigo em Inglês | MEDLINE | ID: mdl-140180

RESUMO

Seven patients affected by Huntington's chorea were given an acute administration of 2-Br-alpha-ergocryptine (CB 154, Sandoz), a direct agonist at dopamine receptor sites. Seven nonobese hospitalized patients were used as controls. Oral administration of CB 154 (2.5 mg) induced a more prompt and consistent rise in plasma growth hormone (GH) levels in patients than in controls. GH levels rose from baseline values of 0.3+/-0.1 ng/ml to mean peak values of 20.4+/-5.1 ng/ml (120-270 min) in choreic subjects and from baseline values of 1.0+/-0.4 ng/ml to mean peak values of 5.7+/-1.6 ng/ml (180-300 min) in control subjects (P less than 0.02). Baseline plasma prolactin (PRL) values were significantly higher in choreic than in control subjects (22.1+/-6.6 ng/ml vs. 8.1+/-1.4 ng/ml, respectively, P less than 0.02); administration of CB 154 induced a more consistent PRL decrease in control than in choreic subjects. Collectively, these results suggest the existence of an abnormal regulation of GH and PRL secretion in Huntington's chorea, probably due to alterations in central dopaminergic neurotransmission.


Assuntos
Bromocriptina , Ergolinas , Hormônio do Crescimento/sangue , Doença de Huntington/sangue , Prolactina/sangue , Adulto , Idoso , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-Idade
17.
J Clin Endocrinol Metab ; 57(3): 537-43, 1983 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-6308030

RESUMO

Most studies of plasma beta-endorphin concentrations in pregnant women show that these are highly elevated. This might indicate a role for opiate peptides during pregnancy and in the fetus-mother relationship. We measured plasma beta-endorphin, beta-lipotropin, and met-enkephalin concentrations in normal and drug-addicted women during pregnancy, labor, and delivery, and in their newborn infants. Peptides were measured by RIA after extraction and concentration on silica columns and separation by high pressure liquid chromatography. In both normal and drug-addicted mothers we found an increase in plasma beta-endorphin during pregnancy, without a concomitant increase in plasma beta-lipotropin or metenkephalin. Only beta-lipotropin increased dramatically in both groups at delivery, whereas beta-endorphin and met-enkephalin remained unchanged. Peptide concentrations in umbilical plasma were similar to those in peripheral plasma of the mothers. On day 1 of life plasma beta-endorphin, beta-lipotropin, and met-enkephalin concentrations in the newborn from normal mothers were higher than in nonpregnant adult subjects and gradually decreased toward normal adult values by day 5 of life. Plasma beta-endorphin, beta-lipotropin, and met-enkephalin concentrations of newborn infants of drug-addicted mothers increased dramatically on day 2 and 3 of life, up to 1000-fold the concentrations of normal adults, and remained elevated up to 40 days after birth. In conclusion, beta-endorphin, beta-lipotropin, and met-enkephalin concentrations during pregnancy are not affected by drug addiction, whereas in the newborn of drug addicted mothers concentrations of these compounds are markedly increased.


Assuntos
Endorfinas/sangue , Recém-Nascido , Complicações na Gravidez/sangue , Efeitos Tardios da Exposição Pré-Natal , Transtornos Relacionados ao Uso de Substâncias/sangue , Adulto , Encefalina Metionina/sangue , Feminino , Sangue Fetal/metabolismo , Humanos , Trabalho de Parto , Gravidez , beta-Endorfina , beta-Lipotropina/sangue
18.
Arch Neurol ; 57(8): 1178-81, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10927798

RESUMO

CONTEXT: It has been reported that the opioid peptide beta-endorphin (BE) has immunosuppressive effects. Interferon beta (IFN-beta) is a well-established therapy for multiple sclerosis (MS), but immunological mechanisms underlying its beneficial effects in MS are partially undefined. OBJECTIVES: To determine BE levels in peripheral blood mononuclear cells (PBMCs) of patients with relapsing-remitting MS during different phases of disease activity and the possible modulating effects of IFN-beta treatment on PBMC BE synthesis in patients with MS. DESIGN: We measured BE levels in blood samples collected from 6 patients with MS who had not experienced clinical changes during the previous 3 months (patients with stable MS) and from 7 patients with MS during a clinical relapse. We also surveyed BE levels in PBMC samples from 8 patients with MS before treatment and for 6 months after the beginning of IFN-beta administration. The control group was 13 healthy subjects. RESULTS: Low PBMC BE levels were detected in patients with stable MS and in those entering IFN-beta treatment compared with control subjects. Increased BE concentrations were observed in MS patients experiencing a clinical relapse compared with patients with stable MS. During IFN-beta treatment, the levels of BE in PBMC samples from patients with MS increased significantly (after 1 month, P =.02; after 3 months, P =.007; and after 6 months, P =.16). CONCLUSIONS: A reduction of BE levels was present in patients with clinically inactive MS. Treatment with IFN-beta seems to induce an increase of this opioid in PBMCs of MS patients. The increase of BE concentration during a clinical relapse may represent a possible control mechanism aimed at counterbalancing the inflammatory phase of the disease. Arch Neurol. 2000;57:1178-1181


Assuntos
Leucócitos Mononucleares/química , Leucócitos Mononucleares/imunologia , Esclerose Múltipla Recidivante-Remitente/imunologia , beta-Endorfina/análise , Adjuvantes Imunológicos/uso terapêutico , Adulto , Feminino , Humanos , Interferon beta/uso terapêutico , Masculino , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Recidiva
20.
Neurology ; 34(4): 516-9, 1984 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-6199690

RESUMO

Methionine-enkephalin, substance P, and homovanillic acid concentrations were measured in the CSF of subjects not affected by neurologic disorders (group 1), and in parkinsonian patients who had a slight or moderate (group 2) or severe (group 3) disability. Homovanillic acid and substance P concentrations in the CSF of groups 2 and 3 were respectively lower and higher than in group 1. On the contrary, an increase in CSF methionine-enkephalin content was found only in group 2. Our results confirm in humans the close relation between the dopaminergic and peptidergic transmissions in the nigrostriatal system that has been observed in experimental animals.


Assuntos
Encefalina Metionina/líquido cefalorraquidiano , Ácido Homovanílico/líquido cefalorraquidiano , Doença de Parkinson/líquido cefalorraquidiano , Fenilacetatos/líquido cefalorraquidiano , Substância P/líquido cefalorraquidiano , Adulto , Idoso , Dopamina/fisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA